on CureVac (NASDAQ:CVAC)
CureVac Secures Patent Win Against BioNTech
CureVac has received a favorable ruling from the European Patent Office regarding its patent EP 3 708 668 B1. BioNTech's challenge, raised in April 2023, was largely dismissed. The patent, concerning a pioneering mRNA technology, remains valid in amended form. A hearing on potential infringement by BioNTech is set for July 1, 2025, in Düsseldorf, Germany.
This decision is significant in the broader legal battle between CureVac and BioNTech, involving six intellectual property rights. CureVac's CEO, Dr. Alexander Zehnder, highlighted the importance of this decision for recognizing the company's contribution to mRNA-based COVID-19 vaccines and its ongoing efforts to expand mRNA medicine.
EP 3 708 668 B1 pertains to a technique enhancing the efficacy of mRNA constructs, crucial for developing transformative medicines. CureVac remains represented by leading law firms in Germany and the U.S.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CureVac news